Quick Answer
Bicara Therapeutics Inc. reported Earnings Per Share Diluted of $2.52 (loss) per share for the year ending 2025.
- Bicara Therapeutics Inc. showed an increase of +37.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Bicara Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $38.23 (loss) per share | Q1 2024: $18.94 (loss) per share | Q2 2024: $19.01 (loss) per share | Q3 2024: $1.60 (loss) per share | Q1 2025: $0.68 (loss) per share | Q2 2025: $0.50 (loss) per share | Q3 2025: $0.67 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Bicara Therapeutics Inc.'s Earnings Per Share Diluted has grown by 97.2%.
- Historical annual values: Fiscal year 2025: $2.52 (loss) per share | Fiscal year 2024: $4.05 (loss) per share | Fiscal year 2023: $89.61 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: